Datasets:

nzindoc

/

dataset-multiple-myeloma

like 0

The influence of previous treatments on the median PFS for Pomalidomide+Dexamethasone (Pd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone (Pd) from APOLLO was 6.9 months with a 95% Confidence Interval (CI) of (5.5, 9.3) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00128-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Pomalidomide+Dexamethasone (Pd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone (Pd) from APOLLO was 6.9 months with a 95% Confidence Interval (CI) of (5.5, 9.3) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00128-5/fulltext)}

The effect of dosage and administration frequency on the median PFS for Pomalidomide+Dexamethasone (Pd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone (Pd) from APOLLO was 6.9 months with a 95% Confidence Interval (CI) of (5.5, 9.3) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00128-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Pomalidomide+Dexamethasone (Pd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone (Pd) from APOLLO was 6.9 months with a 95% Confidence Interval (CI) of (5.5, 9.3) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00128-5/fulltext)}

The correlation between the median PFS for Pomalidomide+Dexamethasone (Pd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone (Pd) from APOLLO was 6.9 months with a 95% Confidence Interval (CI) of (5.5, 9.3) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00128-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Pomalidomide+Dexamethasone (Pd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone (Pd) from APOLLO was 6.9 months with a 95% Confidence Interval (CI) of (5.5, 9.3) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00128-5/fulltext)}

The impact of side effects and adverse reactions on the median PFS for Pomalidomide+Dexamethasone (Pd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone (Pd) from APOLLO was 6.9 months with a 95% Confidence Interval (CI) of (5.5, 9.3) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00128-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Pomalidomide+Dexamethasone (Pd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone (Pd) from APOLLO was 6.9 months with a 95% Confidence Interval (CI) of (5.5, 9.3) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00128-5/fulltext)}

The role of supportive care in improving the median PFS for Pomalidomide+Dexamethasone (Pd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone (Pd) from APOLLO was 6.9 months with a 95% Confidence Interval (CI) of (5.5, 9.3) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00128-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Pomalidomide+Dexamethasone (Pd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone (Pd) from APOLLO was 6.9 months with a 95% Confidence Interval (CI) of (5.5, 9.3) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00128-5/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for Pomalidomide+Dexamethasone (Pd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone (Pd) from APOLLO was 6.9 months with a 95% Confidence Interval (CI) of (5.5, 9.3) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00128-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Pomalidomide+Dexamethasone (Pd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone (Pd) from APOLLO was 6.9 months with a 95% Confidence Interval (CI) of (5.5, 9.3) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00128-5/fulltext)}

The effect of concurrent health conditions on the median PFS for Pomalidomide+Dexamethasone (Pd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone (Pd) from APOLLO was 6.9 months with a 95% Confidence Interval (CI) of (5.5, 9.3) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00128-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Pomalidomide+Dexamethasone (Pd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone (Pd) from APOLLO was 6.9 months with a 95% Confidence Interval (CI) of (5.5, 9.3) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00128-5/fulltext)}

Median PFS for Subcutaneous Daratumumab (Dara SC)?

The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Subcutaneous Daratumumab (Dara SC)? ### Response: The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Comparison of the median PFS for Subcutaneous Daratumumab (Dara SC) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Subcutaneous Daratumumab (Dara SC) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

The impact of patient characteristics on the median PFS for Subcutaneous Daratumumab (Dara SC).

The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Subcutaneous Daratumumab (Dara SC). ### Response: The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

The role of genetic factors in the median PFS for Subcutaneous Daratumumab (Dara SC).

The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Subcutaneous Daratumumab (Dara SC). ### Response: The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

The influence of previous treatments on the median PFS for Subcutaneous Daratumumab (Dara SC).

The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Subcutaneous Daratumumab (Dara SC). ### Response: The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

The effect of dosage and administration frequency on the median PFS for Subcutaneous Daratumumab (Dara SC).

The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Subcutaneous Daratumumab (Dara SC). ### Response: The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

The correlation between the median PFS for Subcutaneous Daratumumab (Dara SC) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Subcutaneous Daratumumab (Dara SC) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

The impact of side effects and adverse reactions on the median PFS for Subcutaneous Daratumumab (Dara SC).

The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Subcutaneous Daratumumab (Dara SC). ### Response: The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

The role of supportive care in improving the median PFS for Subcutaneous Daratumumab (Dara SC).

The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Subcutaneous Daratumumab (Dara SC). ### Response: The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

The influence of disease stage at the start of treatment on the median PFS for Subcutaneous Daratumumab (Dara SC).

The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Subcutaneous Daratumumab (Dara SC). ### Response: The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

The effect of concurrent health conditions on the median PFS for Subcutaneous Daratumumab (Dara SC).

The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Subcutaneous Daratumumab (Dara SC). ### Response: The median progression-free survival (PFS) for the treatment combination of Subcutaneous Daratumumab (Dara SC) from COLUMBA was 5.6 months with a 95% Confidence Interval (CI) of (4.7, 7.6) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Median PFS for Intravenous Daratumumab (Dara IV)?

The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Intravenous Daratumumab (Dara IV)? ### Response: The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Comparison of the median PFS for Intravenous Daratumumab (Dara IV) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Intravenous Daratumumab (Dara IV) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

The impact of patient characteristics on the median PFS for Intravenous Daratumumab (Dara IV).

The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Intravenous Daratumumab (Dara IV). ### Response: The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

The role of genetic factors in the median PFS for Intravenous Daratumumab (Dara IV).

The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Intravenous Daratumumab (Dara IV). ### Response: The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

The influence of previous treatments on the median PFS for Intravenous Daratumumab (Dara IV).

The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Intravenous Daratumumab (Dara IV). ### Response: The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

The effect of dosage and administration frequency on the median PFS for Intravenous Daratumumab (Dara IV).

The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Intravenous Daratumumab (Dara IV). ### Response: The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

The correlation between the median PFS for Intravenous Daratumumab (Dara IV) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Intravenous Daratumumab (Dara IV) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

The impact of side effects and adverse reactions on the median PFS for Intravenous Daratumumab (Dara IV).

The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Intravenous Daratumumab (Dara IV). ### Response: The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

The role of supportive care in improving the median PFS for Intravenous Daratumumab (Dara IV).

The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Intravenous Daratumumab (Dara IV). ### Response: The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

The influence of disease stage at the start of treatment on the median PFS for Intravenous Daratumumab (Dara IV).

The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Intravenous Daratumumab (Dara IV). ### Response: The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

The effect of concurrent health conditions on the median PFS for Intravenous Daratumumab (Dara IV).

The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Intravenous Daratumumab (Dara IV). ### Response: The median progression-free survival (PFS) for the treatment combination of Intravenous Daratumumab (Dara IV) from COLUMBA was 6.1 months with a 95% Confidence Interval (CI) of (4.7, 8.3) ^{[1](https://haematologica.org/article/view/haematol.2021.279459)}

Median PFS for Idecabtagene Vicleucel (Ide-Cel)?

The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Idecabtagene Vicleucel (Ide-Cel)? ### Response: The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

Comparison of the median PFS for Idecabtagene Vicleucel (Ide-Cel) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Idecabtagene Vicleucel (Ide-Cel) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

The impact of patient characteristics on the median PFS for Idecabtagene Vicleucel (Ide-Cel).

The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Idecabtagene Vicleucel (Ide-Cel). ### Response: The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

The role of genetic factors in the median PFS for Idecabtagene Vicleucel (Ide-Cel).

The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Idecabtagene Vicleucel (Ide-Cel). ### Response: The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

The influence of previous treatments on the median PFS for Idecabtagene Vicleucel (Ide-Cel).

The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Idecabtagene Vicleucel (Ide-Cel). ### Response: The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

The effect of dosage and administration frequency on the median PFS for Idecabtagene Vicleucel (Ide-Cel).

The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Idecabtagene Vicleucel (Ide-Cel). ### Response: The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

The correlation between the median PFS for Idecabtagene Vicleucel (Ide-Cel) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Idecabtagene Vicleucel (Ide-Cel) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

The impact of side effects and adverse reactions on the median PFS for Idecabtagene Vicleucel (Ide-Cel).

The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Idecabtagene Vicleucel (Ide-Cel). ### Response: The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

The role of supportive care in improving the median PFS for Idecabtagene Vicleucel (Ide-Cel).

The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Idecabtagene Vicleucel (Ide-Cel). ### Response: The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

The influence of disease stage at the start of treatment on the median PFS for Idecabtagene Vicleucel (Ide-Cel).

The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Idecabtagene Vicleucel (Ide-Cel). ### Response: The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

The effect of concurrent health conditions on the median PFS for Idecabtagene Vicleucel (Ide-Cel).

The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Idecabtagene Vicleucel (Ide-Cel). ### Response: The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-1 was 8.8 months with a 95% Confidence Interval (CI) of (5.6, 11.6) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2024850)}

Median PFS for 2.5 Mg / Kg Belantamab Mafodotin?

The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for 2.5 Mg / Kg Belantamab Mafodotin? ### Response: The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Comparison of the median PFS for 2.5 Mg / Kg Belantamab Mafodotin with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for 2.5 Mg / Kg Belantamab Mafodotin with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

The impact of patient characteristics on the median PFS for 2.5 Mg / Kg Belantamab Mafodotin.

The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for 2.5 Mg / Kg Belantamab Mafodotin. ### Response: The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

The role of genetic factors in the median PFS for 2.5 Mg / Kg Belantamab Mafodotin.

The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for 2.5 Mg / Kg Belantamab Mafodotin. ### Response: The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

The influence of previous treatments on the median PFS for 2.5 Mg / Kg Belantamab Mafodotin.

The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for 2.5 Mg / Kg Belantamab Mafodotin. ### Response: The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

The effect of dosage and administration frequency on the median PFS for 2.5 Mg / Kg Belantamab Mafodotin.

The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for 2.5 Mg / Kg Belantamab Mafodotin. ### Response: The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

The correlation between the median PFS for 2.5 Mg / Kg Belantamab Mafodotin and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for 2.5 Mg / Kg Belantamab Mafodotin and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

The impact of side effects and adverse reactions on the median PFS for 2.5 Mg / Kg Belantamab Mafodotin.

The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for 2.5 Mg / Kg Belantamab Mafodotin. ### Response: The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

The role of supportive care in improving the median PFS for 2.5 Mg / Kg Belantamab Mafodotin.

The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for 2.5 Mg / Kg Belantamab Mafodotin. ### Response: The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for 2.5 Mg / Kg Belantamab Mafodotin.

The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for 2.5 Mg / Kg Belantamab Mafodotin. ### Response: The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

The effect of concurrent health conditions on the median PFS for 2.5 Mg / Kg Belantamab Mafodotin.

The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for 2.5 Mg / Kg Belantamab Mafodotin. ### Response: The median progression-free survival (PFS) for the treatment combination of 2.5 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 2.9 months with a 95% Confidence Interval (CI) of (2.1, 3.7) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Median PFS for 3.4 Mg / Kg Belantamab Mafodotin?

The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for 3.4 Mg / Kg Belantamab Mafodotin? ### Response: The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Comparison of the median PFS for 3.4 Mg / Kg Belantamab Mafodotin with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for 3.4 Mg / Kg Belantamab Mafodotin with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

The impact of patient characteristics on the median PFS for 3.4 Mg / Kg Belantamab Mafodotin.

The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for 3.4 Mg / Kg Belantamab Mafodotin. ### Response: The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

The role of genetic factors in the median PFS for 3.4 Mg / Kg Belantamab Mafodotin.

The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for 3.4 Mg / Kg Belantamab Mafodotin. ### Response: The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

The influence of previous treatments on the median PFS for 3.4 Mg / Kg Belantamab Mafodotin.

The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for 3.4 Mg / Kg Belantamab Mafodotin. ### Response: The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

The effect of dosage and administration frequency on the median PFS for 3.4 Mg / Kg Belantamab Mafodotin.

The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for 3.4 Mg / Kg Belantamab Mafodotin. ### Response: The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

The correlation between the median PFS for 3.4 Mg / Kg Belantamab Mafodotin and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for 3.4 Mg / Kg Belantamab Mafodotin and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

The impact of side effects and adverse reactions on the median PFS for 3.4 Mg / Kg Belantamab Mafodotin.

The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for 3.4 Mg / Kg Belantamab Mafodotin. ### Response: The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

The role of supportive care in improving the median PFS for 3.4 Mg / Kg Belantamab Mafodotin.

The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for 3.4 Mg / Kg Belantamab Mafodotin. ### Response: The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for 3.4 Mg / Kg Belantamab Mafodotin.

The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for 3.4 Mg / Kg Belantamab Mafodotin. ### Response: The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

The effect of concurrent health conditions on the median PFS for 3.4 Mg / Kg Belantamab Mafodotin.

The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for 3.4 Mg / Kg Belantamab Mafodotin. ### Response: The median progression-free survival (PFS) for the treatment combination of 3.4 Mg / Kg Belantamab Mafodotin from DREAMM-2 was 4.9 months with a 95% Confidence Interval (CI) of (2.3, 6.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30788-0/fulltext)}

Median PFS for Ciltacabtagene Autoleucel (Cilta-Cel)?

The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Ciltacabtagene Autoleucel (Cilta-Cel)? ### Response: The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

Comparison of the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

The impact of patient characteristics on the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel).

The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel). ### Response: The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

The role of genetic factors in the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel).

The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel). ### Response: The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

The influence of previous treatments on the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel).

The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel). ### Response: The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

The effect of dosage and administration frequency on the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel).

The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel). ### Response: The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

The correlation between the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

The impact of side effects and adverse reactions on the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel).

The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel). ### Response: The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

The role of supportive care in improving the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel).

The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel). ### Response: The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

The influence of disease stage at the start of treatment on the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel).

The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel). ### Response: The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

The effect of concurrent health conditions on the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel).

The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel). ### Response: The median progression-free survival (PFS) for the treatment combination of Ciltacabtagene Autoleucel (Cilta-Cel) from CARTITUDE-1 was NE months with a 95% Confidence Interval (CI) of (24.5, NE) ^{[1](https://ascopubs.org/doi/10.1200/JCO.22.00842)}

Median PFS for Cilta-Cel?

The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Cilta-Cel? ### Response: The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Comparison of the median PFS for Cilta-Cel with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Cilta-Cel with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The impact of patient characteristics on the median PFS for Cilta-Cel.

The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Cilta-Cel. ### Response: The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The role of genetic factors in the median PFS for Cilta-Cel.

The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Cilta-Cel. ### Response: The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The influence of previous treatments on the median PFS for Cilta-Cel.

The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Cilta-Cel. ### Response: The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The effect of dosage and administration frequency on the median PFS for Cilta-Cel.

The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Cilta-Cel. ### Response: The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The correlation between the median PFS for Cilta-Cel and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Cilta-Cel and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The impact of side effects and adverse reactions on the median PFS for Cilta-Cel.

The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Cilta-Cel. ### Response: The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The role of supportive care in improving the median PFS for Cilta-Cel.

The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Cilta-Cel. ### Response: The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The influence of disease stage at the start of treatment on the median PFS for Cilta-Cel.

The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Cilta-Cel. ### Response: The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The effect of concurrent health conditions on the median PFS for Cilta-Cel.

The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Cilta-Cel. ### Response: The median progression-free survival (PFS) for the treatment combination of Cilta-Cel from CARTITUDE-4 was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Median PFS for Teclistamab?

The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Teclistamab? ### Response: The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

Comparison of the median PFS for Teclistamab with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Teclistamab with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

The impact of patient characteristics on the median PFS for Teclistamab.

The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Teclistamab. ### Response: The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

The role of genetic factors in the median PFS for Teclistamab.

The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Teclistamab. ### Response: The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

The influence of previous treatments on the median PFS for Teclistamab.

The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Teclistamab. ### Response: The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

The effect of dosage and administration frequency on the median PFS for Teclistamab.

The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Teclistamab. ### Response: The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

The correlation between the median PFS for Teclistamab and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Teclistamab and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

The impact of side effects and adverse reactions on the median PFS for Teclistamab.

The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Teclistamab. ### Response: The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

The role of supportive care in improving the median PFS for Teclistamab.

The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Teclistamab. ### Response: The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

The influence of disease stage at the start of treatment on the median PFS for Teclistamab.

The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Teclistamab. ### Response: The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

The effect of concurrent health conditions on the median PFS for Teclistamab.

The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Teclistamab. ### Response: The median progression-free survival (PFS) for the treatment combination of Teclistamab from MajesTEC-1 was 11.3 months with a 95% Confidence Interval (CI) of (8.8, 17.1) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2203478)}

Median PFS for CT103A?

The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None ^{[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for CT103A? ### Response: The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None ^{[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)}

Comparison of the median PFS for CT103A with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None ^{[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for CT103A with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None ^{[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)}

The impact of patient characteristics on the median PFS for CT103A.

The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None ^{[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for CT103A. ### Response: The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None ^{[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)}

The role of genetic factors in the median PFS for CT103A.

The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None ^{[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for CT103A. ### Response: The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None ^{[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)}

The influence of previous treatments on the median PFS for CT103A.

The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None ^{[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for CT103A. ### Response: The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None ^{[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)}